মাল্যাশিয়া - ইংরেজি - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sdn. bhd. - avelumab -

কানাডা - ইংরেজি - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 20mg - cabozantinib (cabozantinib malate) 20mg - antineoplastic agents

কানাডা - ইংরেজি - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 40mg - cabozantinib (cabozantinib malate) 40mg - antineoplastic agents

কানাডা - ইংরেজি - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 60mg - cabozantinib (cabozantinib malate) 60mg - antineoplastic agents

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - ipilimumab, quantity: 213 mg - injection, concentrated - excipient ingredients: trometamol hydrochloride; sodium chloride; mannitol; pentetic acid; polysorbate 80; sodium hydroxide; hydrochloric acid; water for injections - melanoma,winglore, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma.,winglore, in combination with nivolumab, is indicated for the treatment of patients with unresectable or metastatic melanoma. the approval of this indication is based on a pre-specified comparison to ipilimumab monotherapy. all analyses comparing nivolumab monotherapy with the nivolumab/ipilimumab combination are descriptive.,renal cell carcinoma (rcc),winglore, in combination with nivolumab, is indicated for the treatment of patients with intermediate/poor-risk, previously untreated advanced renal cell carcinoma.,non-small cell lung cancer (nsclc),winglore, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (nsclc) with no egfr or alk genomic tumour aberrations.,malignant pleural mesothelioma (mpm),winglore, in combination with nivolumab, is indicated for the first-line treatment of patients with unresectable malignant pleural mesothelioma.,oesophageal squamous cell carcinoma (oscc),winglore in combination with nivolumab is indicated for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression greater than or equal to 1% as determined by a validated test.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - ipilimumab, quantity: 53.5 mg - injection, concentrated - excipient ingredients: trometamol hydrochloride; sodium chloride; mannitol; pentetic acid; polysorbate 80; sodium hydroxide; hydrochloric acid; water for injections - melanoma,winglore, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma.,winglore, in combination with nivolumab, is indicated for the treatment of patients with unresectable or metastatic melanoma. the approval of this indication is based on a pre-specified comparison to ipilimumab monotherapy. all analyses comparing nivolumab monotherapy with the nivolumab/ipilimumab combination are descriptive.,renal cell carcinoma (rcc),winglore, in combination with nivolumab, is indicated for the treatment of patients with intermediate/poor-risk, previously untreated advanced renal cell carcinoma.,non-small cell lung cancer (nsclc),winglore, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (nsclc) with no egfr or alk genomic tumour aberrations.,malignant pleural mesothelioma (mpm),winglore, in combination with nivolumab, is indicated for the first-line treatment of patients with unresectable malignant pleural mesothelioma.,oesophageal squamous cell carcinoma (oscc),winglore in combination with nivolumab is indicated for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression greater than or equal to 1% as determined by a validated test.

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

celtic biotech iowa, inc. - crotalus durissus terrificus venom (unii: 2xf6i0446g) (crotalus durissus terrificus venom - unii:2xf6i0446g), cardiotoxin iii (unii: 0qbh3y8m6j) (cardiotoxin iii - unii:0qbh3y8m6j) - crotalus durissus terrificus venom 4 [hp_x] in 1 ml - according to the fda reference text “clarkes’ materia medica 1900”; crotalus venom preparations are indicated as homeopathic medications for numerous conditions but especially; cancers. tongue, inflammation of ; cancer of. clinical experience shows that crotoxin also provide relief from some forms of pain. cobra venom preparations are indicated as homeopathic medications for several conditions but especially for; angina faucium, angina pectoris, asthma, dysmenia (painful menses), grief (depression), headache (migraine), pain in ovaries (ovarian cysts), spinal irritation (back pain) and sore throat. cardiotoxin is the principal active analgesic component. ctc-310 is intended to be used as a monotherapy. clinical experience suggests that concurrent use of radio- or chemotherapy may inhibit the activity of the drug. as the known receptors include those sensitive to nicotine is it is likely that nicotine will inhibit the activity of crotoxin.

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

celtic biotech iowa, inc. - crotalus durissus terrificus venom (unii: 2xf6i0446g) (crotalus durissus terrificus venom - unii:2xf6i0446g) - crotalus durissus terrificus venom 4 [hp_x] in 1 ml - according to clarkes’s materia medica, crotalus venom preparations are indicated as homeopathic medications for; amblyopia. apoplexy. appendicitis. bilious fever. boils. cancers. carbuncles. cerebro-spinal meningitis. chancre. ciliary neuralgia. convulsions. delirium tremens. dementia. diphtheria. dysmenorrhoea. dyspepsia. ears, discharges from. ecchymosis. epilepsy. eyes, affections of. erysipelas, face, eruption on ; distortion of. haematuria. hemorrhagic diathesis. headache. heart, affections of. herpes. hydrophobia. intestinal haemorrhage. jaundice. keratitis. liver, disorders of. lungs, affections of, mastitis. measles. milk-leg. meningitis. ovaries, affections of. ozaena, palpitation. peritonitis. perityphlitis. phlebitis. psoriasis palmaris. purpura. pyaemia. remittent fever. rheumatism. scarlatina. sleeplessness. small-pox. stings. sunstroke. syphilis. tetanus. thirst. tongue, inflammation of ; cancer of. ulcers. urticaria. vaccination, effects of. varicosis. varicocele. vomiting, bilious. white-leg.

সিঙ্গাপুর - ইংরেজি - HSA (Health Sciences Authority)

agilent technologies singapore (international) pte ltd - pathology - pd-l1 ihc 28-8 pharmdx is a qualitative immunohistochemical assay using monoclonal rabbit anti-pd-l1, clone 28-8 intended for use in the detection of pd-l1 protein in formalin-fixed, paraffin-embedded (ffpe) non-squamous non-small cell lung cancer (nsnsclc) and muscle invasive urothelial carcinoma (miuc) tissues using envision flex visualization system on autostainer link 48. pd-l1 protein expression in nsnsclc and miuc is determined by using % tumor cell expression, which is the percentage of evaluable tumor cells exhibiting partial or complete membrane staining at any intensity. pd-l1 ihc 28-8 pharmdx is indicated as an aid in identifying miuc patients with ≥ 1% tumor cell pd-l1 expression for treatment with opdivo® (nivolumab). pd-l1 expression (≥ 1% or ≥ 5% or ≥ 10% tumor cell expression), as detected by pd-l1 ihc 28-8 pharmdx in non-squamous nsclc (nsnsclc) may be associated with enhanced survival from opdivo® (nivolumab).

সিঙ্গাপুর - ইংরেজি - HSA (Health Sciences Authority)

roche diagnostics asia pacific pte ltd - pathology - ventana pd-l1 (sp263) assay is intended for the qualitative detection of the programmed death ligand 1 (pd-l1) protein in formalin-fixed, paraffin-embedded (ffpe) non-small cell lung cancer (nsclc) tissue stained with optiview dab ihc detection kit on a benchmark ihc/ish instrument. pd-l1 expression in tumor cell (tc) membrane as detected by ventana pd-l1 (sp263) assay in nsclc is indicated as an aid in identifying patients for treatment with imfinzi™ (durvalumab), keytruda® (pembrolizumab) and tecentriq® (atezolizumab). pd-l1 expression in tumor cell (tc) membrane as detected by ventana pd-l1 (sp263) assay in nsclc may be associated with enhanced survival from opdivo® (nivolumab).